炎症性肠病合并胆系疾病的诊治策略

刘芸; 刘玉兰

doi:10.3969/j.issn.1001-5256.2020.07.003

炎症性肠病合并胆系疾病的诊治策略

DOI: 10.3969/j.issn.1001-5256.2020.07.003

刘芸,
刘玉兰

1. 北京大学人民医院消化科
2. 北京大学人民医院免疫介导消化疾病研究中心

详细信息

中图分类号: R574;R575
计量
- 文章访问数: 1210
- HTML全文浏览量: 9
- PDF下载量: 198
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Diagnosis and treatment strategies for inflammatory bowel disease with concomitant biliary diseases

Liu Yun,
Liu YuLan

a. Department of Gastroenterology; b. Clinical Center of Immune-mediated Digestive Diseases, Peking University People’s Hospital, Beijing 100044, China

摘要

摘要:
炎症性肠病(IBD)是一类肠道慢性非特异性炎症性疾病,主要包括溃疡性结肠炎和克罗恩病。IBD患者除消化道症状外,常合并其他肠外表现,可累及骨骼肌肉、皮肤、眼部、肝胆、胰腺、神经、泌尿生殖、肺部、心脏、血液等多系统。胆系疾病是IBD的肠外表现之一,主要包括原发性硬化性胆管炎、IgG4相关性硬化性胆管炎、原发性胆汁性胆管炎、胆石症等。胆系疾病可表现为无症状患者一过性肝功能异常,也可能是威胁生命的肝衰竭,但不同的胆系疾病治疗及预后大有不同,需仔细鉴别诊断。就IBD合并胆系疾病进行评述,以期帮助临床医师熟悉IBD患者胆系疾病的临床表现及诊治策略。
- 炎症性肠病 /
- 肝硬化,胆汁性 /
- 胆管炎,硬化性 /
- 诊断 /
- 治疗学
Abstract:
Inflammatory bowel disease( IBD) is a series of non-specific chronic inflammatory diseases,including ulcerative colitis and Crohn's disease. Besides gastrointestinal symptoms,IBD patients often have extraintestinal symptoms which may involve various systems such as the skeleton and muscle,skin,eyes,liver and gallbladder,pancreas,nerves,urogenital system,lungs,heart,and blood. Biliary diseases are extraintestinal manifestations of IBD and mainly include primary sclerosing cholangitis,IgG4-associated sclerosing cholangitis,primary biliary cirrhosis,and cholelithiasis. Biliary diseases may manifest as transient abnormal liver function in asymptomatic patients and even life-threatening liver failure,and different biliary diseases may have different treatment methods and prognoses and thus require careful differential diagnosis. This article reviews biliary diseases in IBD patients,in order to help clinicians get familiar with the clinical manifestations and diagnosis and treatment strategies for biliary diseases in IBD patients.
- inflammatory bowel disease /
- liver cirrhosis,biliary /
- cholangitis,sclerosing /
- diagnosis /
- therapeutics

HTML全文

参考文献(36)

[1]BERNSTEIN CN,BLANCHARD JF,RAWSTHORNE P,et al.The prevalence of extraintestinal diseases in inflammatory bowel disease:Apopulation-based study[J].Am J Gastroenterol,2001,96(4):1116-1122．

[2]GARBER A,REGUEIRO M.Extraintestinal manifestations of inflammatory bowel disease:Epidemiology,etiopathogenesis,and management[J].Curr Gastroenterol Rep,2019,21(7):31．

[3]FENG Y,LIU YL.Progress of the extraintestinal manifestations of inflammatory bowel disease[J].Chin J Gastroenterol Hepatol,2015,24(6):631-640.(in Chinese)冯云，刘玉兰．炎症性肠病的肠外表现的研究进展[J]．胃肠病学和肝病学杂志，2015,24(6):631-640．

[4]VAVRICKA SR,BRUN L,BALLABENI P,et al.Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort[J].Am J Gastroenterol,2011,106(1):110-119．

[5]VAVRICKA SR,ROGLER G,GANTENBEIN C,et al.Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort[J].Inflamm Bowel Dis,2015,21(8):1794-1800．

[6]KARLSEN TH.Primary sclerosing cholangitis:50 years of a gut-liver relationship and still no love?[J].Gut,2016,65(10):1579-1581．

[7]SRENSEN J，NIELSEN OH,ANDERSSON M,et al.Inflammatory bowel disease with primary sclerosing cholangitis:A Danish population-based cohort study 1977-2011[J].Liver Int,2018,38(3):532-541．

[8]GUERRA I,BUJANDA L,CASTRO J,et al.Clinical characteristics,associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients:A multicentre retrospective cohort study[J].J Crohns Colitis,2019,13(12):1492-1500．

[9]KARLSEN TH,FOLSERAAS T,THORBURN D,et al.Primary sclerosing cholangitis-a comprehensive review[J].J Hepatol,2017,67(6):1298-1323．

[10]de VRIES AB,JANSE M,BLOKZIJL H,et al.Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis[J].World JGastroenterol,2015,21(6):1956-1971．

[11]MERTZ A,NGUYEN NA,KATSANOS KH,et al.Primary sclerosing cholangitis and inflammatory bowel disease comorbidity:An update of the evidence[J].Ann Gastroenterol,2019,32(2):124-133．

[12]HARBORD M,ANNESE V,VAVRICKA SR,et al.The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J].J Crohns Colitis,2016,10(3):239-254．

[13]RABINOVITZ M,GAVALER JS,SCHADE RR,et al.Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease?A study of sixty-six subjects[J].Hepatology,1990,11(1):7-11．

[14]YANAI H,MATALON S,ROSENBLATT A,et al.Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel disease[J].J Crohns Colitis,2015,9(2):177-184．

[15]LUDWIG J,BARHAM SS,LARUSSO NF,et al.Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis[J].Hepatology,1981,1(6):632-640．

[16]CHAPMAN MH,THORBURN D,HIRSCHFIELD GM,et al.British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis[J].Gut,2019,68(8):1356-1378．

[17]CHAZOUILLRES O.24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis:A new“urso saga”on the horizon?[J].J Hepatol,2017,67(3):446-447．

[18]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of primary sclerosing cholangitis(2015)[J].J Clin Hepatol,2016,32(1):23-31.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性硬化性胆管炎诊断和治疗专家共识(2015)[J]．临床肝胆病杂志，2016,32(1):23-31．

[19]SHAH A,CRAWFORD D,BURGER D,et al.Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease:A systematic review and meta-analysis[J].Semin Liver Dis,2019,39(4):432-441．

[20]JESS T,RUNGOE C,PEYRIN-BIROULET L.Risk of colorectal cancer in patients with ulcerative colitis:A meta-analysis of population-based cohort studies[J].Clin Gastroenterol Hepatol,2012,10(6):639-645．

[21]ZHENG HH,JIANG XL.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease:A meta-analysis of 16 observational studies[J].Eur J Gastroenterol Hepatol,2016,28(4):383-390．

[22] Inflammatory Bowel Disease Group,Chinese Society of Gastroenterology,Chinese Medical Association.Chinese consensus on diagnosis and treatment in inflammatory bowel disease(2018,Beijing)[J].Chin JDig,2018,38(5):292-311.(in Chinese)中华医学会消化病学分会炎症性肠病学组．炎症性肠病诊断与治疗的共识意见(2018年，北京)[J]．中华消化杂志，2018,38(5):292-311．

[23]AABAKKEN L,KARLSEN TH,ALBERT J,et al.Role of endoscopy in primary sclerosing cholangitis:European Society of Gastrointestinal Endoscopy(ESGE)and European Association for the Study of the Liver(EASL)clinical guideline[J].Endoscopy,2017,49(6):588-608．

[24]HUAI JP,DING J,YE XH,et al.Inflammatory bowel disease and risk of cholangiocarcinoma:Evidence from a meta-analysis of population-based studies[J].Asian Pac J Cancer Prev,2014,15(8):3477-3482．

[25]ANANTHAKRISHNAN AN,CAGAN A,GAINER VS,et al.Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease[J].J Crohns Colitis,2014,8(9):956-963．

[26]BOWLUS CL,LIM JK,LINDOR KD.AGA clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis:Expert review[J].Clin Gastroenterol Hepatol,2019,17(12):2416-2422．

[27]CHARATCHAROENWITTHAYA P,ANGULO P,ENDERS FB,et al.Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis[J].Hepatology,2008,47(1):133-142．

[28]BJRNSSON E,OLSSON R,BERGQUIST A,et al.The natural history of small-duct primary sclerosing cholangitis[J].Gastroenterology,2008,134(4):975-980．

[29] CHEN CH,LIN CL,KAO CH.Association between inflammatory bowel disease and cholelithiasis:A nationwide population-based cohort study[J].Int J Environ Res Public Health,2018,15(3):513．

[30]GIZARD E,FORD AC,BRONOWICKI JP,et al.Systematic review:The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease[J].Aliment Pharmacol Ther,2014,40(1):3-15．

[31]Editorial Board of Chinese Journal of Digestion,Cooperation Group of Hepatobiliary Diseases of Chinese Society of Gastroenterology.Consensus on diagnosis and treatment of chronic cholecystitis and gallstones in China(2018)[J].J Clin Hepatol,2019,35(6):1231-1236.(in Chinese)中华消化杂志编辑委员会，中华医学会消化病学分会肝胆疾病协作组．中国慢性胆囊炎、胆囊结石内科诊疗共识意见(2018年)[J]．临床肝胆病杂志，2019,35(6):1231-1236．

[32]DASTIS SN,LATINNE D,SEMPOUX C,et al.Ulcerative colitis associated with Ig G4 cholangitis:Similar features in two HLA identical siblings[J].J Hepatol,2009,51(3):601-605．

[33]DESHPANDE V,ZEN Y,CHAN JK,et al.Consensus statement on the pathology of Ig G4-related disease[J].Mod Pathol,2012,25(9):1181-1192．

[34]POLYCHRONOPOULOU E,LYGOURA V,GATSELIS NK,et al.Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis:Consider primary biliary cholangitis not always primary sclerosing cholangitis[J].BMJ Case Rep,2017,2017:bcr2017220824．

[35]XIAO WB,LIU YL.Primary biliary cirrhosis and ulcerative colitis:Acase report and review of literature[J].World J Gastroenterol,2003,9(4):878-880．

[36]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988.

施引文献

资源附件(0)

访问统计